 Genetic Technologies Limited ASX: GTG; NASDAQ: GENE the Company, a leader in the development of genetic risk assessment tests, today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale in a registered direct offering of 1,028,574 American Depositary Shares ADSs, each representing six hundred 600 of the Companys ordinary shares, at a purchase price of 1.75 per ADS. The gross proceeds to the Company from this offering are expected to be approximately 1.8 million, before deducting the placement agents fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering to support the introduction and distribution of its new products in the United States, for general product research and development, including the development of polygenic risk tests with TGen in the United States, for implementation of its consumer initiated testing platform, and for working capital. 